Status and phase
Conditions
Treatments
About
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Full description
This study is a phase 1, open-label, multicenter, dose-escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and to evaluate the safety, tolerability, and preliminary antitumor activity of STRO-002 in adult subjects with advanced epithelial ovarian cancer (EOC), including fallopian or primary peritoneal cancer, and endometrial cancer. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this phase 1 study. Subjects enrolled in the study will be required to have progressive or recurrent disease after standard approved therapy as defined in the study eligibility criteria. The study has completed dose escalation and is currently in dose expansion, enrolling endometrial and ovarian cancer subjects.
All subjects enrolled on the study are required to have tumor tissue for determining folate receptor alpha (FolRα) expression levels, either from a prior surgery or tumor biopsy or from a biopsy performed during study screening. The testing for FolRα is done via an ICH assay. A minimum level of FolRα expression is required for enrollment for endometrial cancer but not for ovarian cancer.
Study drug, STRO-002, is administered by intravenous (IV) infusion on day 1 of 21-day cycles. Clinical evaluations and/or laboratory tests will be performed at a pre-specified schedule-weekly for cycles 1-4, and at the beginning of every cycle starting with cycle 5 as described in the schedule of assessments. Samples for PK analysis will occur at specific times on days 1, 8, and 15 of cycles 1 and 4, Day 1 of cycles 2, 3, and 5 and at the end of treatment (EOT) visit. The study requires imaging with a CT or MRI scan of the chest abdomen and pelvis at screening, every 6 weeks after enrollment for the first 18 weeks, then every 9 weeks, and at the end of treatment (EOT) visit. Additional X-rays may be required to confirm disease responses and per local institution standard of care.
Additional clinical evaluations and lab testing may occur at the discretion of the investigator.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 18 years
Measurable disease per RECIST 1.1
ECOG performance status (0-1)
Life expectancy > 3 months
Pathological confirmation of disease under study (historical information, diagnosis, pathology report, etc)
Relapsed and/or progressive disease
Dose Expansion Cohorts A and C (Ovarian Cancer):
Dose Expansion Cohort B (Endometrial Cancer):
Fresh or archival tumor tissue samples
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
160 participants in 1 patient group
Loading...
Central trial contact
Craig Berman, MD; Michael Palumbo
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal